• The role of enterovirus infections in the development of exanthematous disease in children: clinical and epidemiological features and the possibilities of drug correction

The role of enterovirus infections in the development of exanthematous disease in children: clinical and epidemiological features and the possibilities of drug correction

SOVREMENNAYA PEDIATRIYA.2017.5(85):19-24; doi 10.15574/SP.2017.85.19

Usachova O. V.
Zaporizhzhia State Medical University, Ukraine

Objective: To study the clinical progression of enterovirus exanthematous diseases in children and to analyze the efficiency of advanced therapy.
Material and methods. The medical records of 29 patients with infectious exanthema and/or enanthema were analyzed. In all patients a complete clinical and laboratory examination at the hospital of the 3rd level of medical care were provided. Enteroviral RNA in patients' faeces by using PCR was investigated. 16 patients as a complex therapy were administered a drug containing hiporhaminum in the form of dry refined extract obtained from the sea buckthorn leaves (Erebra®).
Results. Only in 55.2% of cases suspected of EV-exanthema confirmed the etiology of the disease. The use of the herbal remedy, which is made from sea buck-thorn, had a definite positive effect on the specific symptoms of enterovirus infection exanthema and enanthema. In patients who were administered hiporhaminum, the decreased appetite normalization was observed faster due to the oropharyngeal pain relief. Against the background of the drug intake, the need of oropharyngeal antiseptics, anesthetics, and saline nasal solutions, as well as the duration of rash on the skin, were decreased.
Conclusions. Enteroviruses are common pathogens of diseases with rash and vesicular lesions of the oral mucosa (every second patient is involved). Treatment efficacy of Erebra® in children with enterovirus exanthematous diseases is shown that is manifested in the decreased duration of the main symptoms exanthema and enanthema.
Key words: enterovirus infection, exanthema, enanthema, hiporhaminum, children.


1. Abaturov AE. (2012). Kationnyie antimikrobnyie peptidyi sistemyi nespetsificheskoy zaschityi respiratornogo trakta: defenzinyi i katelitsidinyi. Defenzinyi — molekulyi, perezhivayuschie renessans. Chast 4. Zdorove rebenka. 2: 154—160.

2. Bortnikova VV. (2011). Eksperimentalnoe izuchenie bezopasnosti giporamina — novogo fitopreparata protivovirusnogo deystviya. Biomeditsina. 3: 106—108.

3. Ershova IB. (2014). Effektivnost giporamina (Erebra) v lechenii i profilaktiki virusnyih zabolevaniy u detey. Zdorove rebenka. 8: 110—113.

4. Kanaeva OI. (2014). Enterovirusnaya infektsiya: mnogoobrazie vozbuditeley i klinicheskih form. Infektsiya i immunitet. 4; 1: 27—36.

5. Kramarev SO, Vigovskaya OV. (2016). Innovations in the treatment and prevention of acute respiratory viral infections in children. Sovremennaya pediatriya. 1(73): 2—7.

6. Ershova IB, Kosenko VS, Osyichnyuk LM et al. (2009). Liposomnyie formyi interferonov v pediatricheskoy praktike pri lechenii ORVI u detey. Zdorove rebenka. 2(17): 20—23.

7. Kryuchko TA, Kushnereva TV, Ostapenko VP, Kolenko IA. (2014). Problematic issues of outpatient management of children with acute respiratory viral infections. Sovremennaya pediatriya. 8(64): 65—68.

8. Begaydarova RH, Starikov YuG, Devdariani HG et al. 2013. Sovremennyie osobennosti nekotoryih klinicheskih form enterovirusnoy infektsii u detey. Mezhdunarodnyiy zhurn eksperiment obrazovaniya. 11: 34—36.

9. Yulish EI, Chernyisheva OE. (2014). Etiopatogeneticheskaya terapiya ostryih respiratornyih virusnyih infektsiy u detey. Zdorove rebenka. 1: 129—133.

10. Medici MC, Tummolo F, Arcangeletti A et al. (2016). A cluster of Enterovirus 71 subgenogroup C2 in a nursery school, Italy, 2014. New Microbiologica. 39(3): 94.

11. Xu F, Zhao X, Hu S et al. (2016). Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry. Scientific Reports. 6: 14. https://doi.org/10.1038/srep33150

12. Arimboor R, Arumughan C. (2012). Effect of polymerization on antioxidant and xanthine oxidase inhibitory potential of sea buckthorn (H. rhamnoides) proanthocyanidins. J Food Sci. 77(10): 1036-41. http://www.ncbi.nim.nih.gov/pubmed/22938149. https://doi.org/10.1111/j.1750-3841.2012.02884.x; PMid:22938149

13. Ooi MH, Wong SC, Lewthwaite P et al. (2010). Clinical features, diagnosis and management of human enterovirus 71 infection. Lancet Neurol. 9; 11: 1097—1105. https://doi.org/10.1016/S1474-4422(10)70209-X

14. Huaman JL, Carrion G, Ampuero JS et al. (2016). .Enterovirus-71 genotype C isolated in Peru between 2006 and 2009. Journal of clinical virology. 85: 40—43. https://doi.org/10.1016/j.jcv.2016.10.023; PMid:27833060

15. Kemball CC, Alirezaei M, Whitton JL. (2010). Type B coxsackieviruses and their interactions with the innate and adaptive immune systems. Future Microbiol. 5; 9: 1329—1347. https://doi.org/10.2217/fmb.10.101; PMid:20860480 PMCid:PMC3045535

16. Li W, Gao HH, Zhanq Q et al. (2016). Large outbreak of herpangina in children caused by enterovirus in summer of 2015 in Hangzhou, China. Journal of Scientific Reports. 6: 353—388. https://doi.org/10.1038/srep35388

17. Duong V, Mey C, Eloit M et al. (2016). Molecular epidemiology of human enterovirus 71 at the origin of an epidemic of fatal hand, foot and mouth disease cases in Cambodia. Emerging Microbes & Infections. 5(9): 104. https://doi.org/10.1038/emi.2016.101; PMid:27651091 PMCid:PMC5113052

18. Zhong T, Zhang LY, Wang ZY et al. (2017). Rheum emodin inhibits enterovirus 71 viral replication and affects the host cell cycle environment. Acta Pharmacologica Sinica. 38: 392—401. https://doi.org/10.1038/aps.2016.110; PMid:27840410

19. Solomon T, Lewthwaite P, Perera D et al. (2010). Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 11; 10: 778—790. https://doi.org/10.1016/S1473-3099(10)70194-8